Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Rigetti Computing Inc (RGTI) Price & Performance

Abeona Therapeutics IncTrade
Rigetti Computing IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Rigetti Computing Inc — how do they compare? Abeona Therapeutics Inc trades at $8.22 (market cap $421.19M), while Rigetti Computing Inc trades at $18.47 (market cap $6.04B). The key difference: Rigetti Computing Inc is far larger — about 14.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals.

ABEORGTI
Market Cap
$421.19M$6.04B
Sector
HealthTechnology
52-Week High
$7.46$56.34
52-Week Low
$4.17$12.90
Enterprise Value
$276.10M$5.65B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.

Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.

Rigetti Computing Inc

Rigetti Computing (RGTI) trades at $18.42, up 4.36% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported Q2 2026 revenue growth of 185% to $5.1 million, beating estimates, but posted a net loss of $0.05 per share, missing expectations. Despite heavy operating losses and negative margins, analyst sentiment remains strongly positive with 85.7% recommending Buy, driven by government backing and quantum computing potential.

The outlook for RGTI is high-risk, high-reward, offering exposure to the emerging quantum computing sector with significant government and commercial interest. However, persistent negative profitability, high cash burn, and intense competition from peers like IonQ pose substantial risks to shareholder value. Investment suitability is limited to those tolerant of speculative, early-stage company volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Rigetti Computing Inc

Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.

Read more on RGTI